Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Vaxcyte

Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock.

For growth-focused biotech investors, Vaxcyte is no longer just a science story.

Barchart

Sugar starts corroding your teeth within seconds – here’s how to protect your pearly whites from decay

Between Halloween candy, Thanksgiving pies and holiday cookies, the end of the year is often packed with opportunities to consume sugar. But what happens in your mouth during those first minutes and hours after eating those sweets?

The Conversation

Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown

Thermo Fisher Scientific Inc. (NYSE:TMO) is tapping the U.S. investment-grade bond market with a four-part, dollar-denominated offering, as companies move to secure funding ahead of a potential U.S. government shutdown.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

2 ‘Strong Buy’ Growth Stocks That Could Gain More Than 340%

A volatile market presents the perfect opportunity to grab outstanding stocks at a bargain.

Barchart

Why Wall Street Rates These 2 Russell 2000 Stocks a “Strong Buy”

These two biotech companies look poised to deliver in the coming year.

Barchart

Pharma Showdown: Evaluating Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX) Stock Performance Under the Microscope

The pharmaceutical landscape is evolving in response to the shift toward sedentary living and is driven by substantial investments in R&D and advanced technologies. Against this backdrop, which of the two pharma stocks, Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX), could generate better returns? Let’s find out….

StockNews.com

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline B

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Organisations

Medical Pharmaceuticals

125 stories

US Food and Drug Administration

63 stories

Thermo Fisher Scientific

Thermo Fisher Scientific Inc

12 stories

Pulse Biosciences

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

416,792 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.